Tirzepatide vs semaglutide: meta-analysis

A systematic review and meta-analysis published in Clinical Obesity in October 2026 (PMID 42670242) set out to synthesise the comparative efficacy of tirzepatide versus semaglutide for weight loss in adults with overweight or obesity^[1]. The analysis pooled trial data from both head-to-head and indirect comparisons to produce a consolidated picture of where the two drugs stand relative to each other, beyond what any single study can say alone.

The clinical question is not new, but the evidence base has grown substantially over the past two years. SURMOUNT-5, the first randomised head-to-head trial of tirzepatide and semaglutide in adults with obesity without type 2 diabetes, published its primary results in the New England Journal of Medicine in 2025. Tirzepatide produced a mean 20.2% body-weight reduction at 72 weeks, compared with 13.7% for semaglutide^[2]. That 6.5 percentage-point gap was statistically significant on every secondary endpoint the trial measured. The 2026 meta-analysis incorporates SURMOUNT-5 alongside earlier network and indirect comparison studies to ask whether the gap holds when all the available evidence is pooled.

What a meta-analysis adds to a single trial

Head-to-head trials answer a precise question in a defined population. A meta-analysis asks whether the finding generalises across populations and study designs. SURMOUNT-5 enrolled 751 adults without type 2 diabetes, following a specific titration protocol, at sites in the United States and Puerto Rico. Earlier trials like SURMOUNT-1, which enrolled 2,519 adults on tirzepatide or placebo and produced a mean 20.9% body-weight reduction at the 15 mg dose^[3], were not designed to compare tirzepatide against semaglutide directly. Indirect comparisons and network meta-analyses attempt to bridge that gap by modelling shared comparator arms across trials.

When multiple indirect comparisons and one direct head-to-head trial all point in the same direction, the meta-analysis gives clinicians and payers a single summary effect size they can use in clinical decision-making and formulary negotiations. That summary is the main contribution of the 2026 Clinical Obesity paper.

The evidence on tirzepatide versus semaglutide

The mechanistic basis for a tirzepatide advantage over semaglutide is pharmacological. Tirzepatide is a dual GIP and GLP-1 receptor agonist; semaglutide targets GLP-1 alone. The GIP pathway contributes to energy expenditure and adipocyte lipid handling through mechanisms distinct from those the GLP-1 pathway engages. Whether dual agonism alone explains the weight-loss difference, or whether titration ceiling and dosing schedules also play a role, remains an open question in the literature. What the trial programme has established consistently is that tirzepatide produces numerically greater weight loss than semaglutide when both are titrated to maximum tolerated doses^[2].

The safety profiles of the two drugs are broadly similar. Gastrointestinal events, primarily nausea, diarrhoea, vomiting, and abdominal discomfort, are the dominant adverse effect class for both agents, concentrated in the dose-escalation phase, and mostly mild to moderate in severity^[4]. SURMOUNT-5 found no meaningful difference in the GI burden between arms, and that finding is consistent with what the individual trial programmes for each drug have reported.

What the meta-analysis does not settle

A meta-analysis is only as reliable as the studies it pools. If trials differ in design, population, comparator dose, or duration, the pooled estimate may obscure real variation. The 2026 Clinical Obesity paper pools data from trials that vary on all of those dimensions. The headline finding, that tirzepatide produces greater mean weight loss than semaglutide, is consistent across the body of evidence, but the precise magnitude of the difference depends on which studies are included and how heterogeneity is handled.

Long-term durability is a separate question that no individual trial in the meta-analysis fully answers. The available data extend to 72 weeks in the head-to-head trial and up to 176 weeks in the SURMOUNT-1 three-year extension. Whether the relative advantage for tirzepatide persists, narrows, or widens at five or ten years of treatment is not something any published trial has yet addressed for either agent.

Cardiovascular outcomes are also absent from the weight-loss trial programme for tirzepatide. Semaglutide has the SELECT trial behind it, which showed a 20% reduction in major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease but without diabetes. A tirzepatide cardiovascular outcomes trial is ongoing, but its primary data have not been published at the time of this article.

What we do not yet know

The 2026 meta-analysis reflects the evidence available at the time of its literature search, which preceded several trials still in progress. Real-world studies, including large claims-database analyses and prospective observational cohorts, will eventually add persistence and effectiveness data that randomised trials cannot provide. The SHAPE retrospective cohort, which followed 9,916 adults with overweight or obesity without type 2 diabetes, found a 16.5% mean weight loss at one year on tirzepatide versus 14.1% on semaglutide 2.4 mg^[2]; that gap is smaller than in the head-to-head trial, likely because real-world dose titration is less consistent than trial-protocol titration.

Access and cost remain unresolved by clinical evidence. Whether a patient in a given country can obtain either drug, at what out-of-pocket cost, and under what coverage conditions varies by market and changes frequently. Country-specific regulatory status and prescribing information for tirzepatide are covered separately on the regulation pages of this site.

This article is for informational purposes only and does not constitute medical advice. Consult a healthcare provider before making any treatment decisions.